Stenabolic is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
TAN-821 is an opioid drug which was originally reported as an agonist for the putative ε-opioid receptor, however this is now thought not to be a separate opioid receptor in its own right but is more likely a heteromer made from hybridisation of known opioid receptor subunits. It has subsequently been shown to have potent affinity for the kappa opioid receptor.
In September 2000, up to $50 million worth of Taco Bell-branded shells were recalled from supermarkets. The shells contained a variety of genetically modified corn called StarLink that was not approved for human consumption. StarLink was approved only for use in animal feed because of questions about whether it can cause allergic reactions in people. It was the first-ever recall of genetically modified food (GMO). Corn was not segregated at grain elevators and the miller in Texas did not order that type. In 2001, Tricon Global announced a $60 million settlement with the suppliers. They stated that it would go to Taco Bell franchisees and TGR would not take any of it.
== Entrepreneurship == Mrksich has been an active entrepreneur over the past twenty years. He co-founded SAMDI Tech in 2011, which uses his label-free assay technology to perform high throughput screens for pharmaceutical companies. SAMDI Tech entered into a partnership with Charles River Laboratories in 2018 and was purchased by CRL in 2023. Mrksich also co-founded WMR Biomedical in 2008, with George Whitesides and Carmichael Roberts to develop resorbable stent materials; this company was renamed Lyra Therapeutics and had an IPO in 2020 (NASDAQ LYRA) and has drug-eluting stents in clinical trials for ear, nose and throat disease, including chronic rhinosinusitis. Mrksich has recently founded ModuMab Therapeutics, which applies his megamolecule technology to creating antibody mimics for a broad range of diseases.
=== Healthcare === Kiggans voted against extending Affordable Care Act subsidies in December 2025. Kiggans supports banning abortions after fifteen weeks of pregnancy, except for in cases of rape, incest, or to protect the life of the mother. In June 2022, she expressed support for the U.S. Supreme Court's ruling in Dobbs v. Jackson Women's Health Organization, which overruled Roe v. Wade.
Sources: en.wikipedia.org
In January 2023, Vice President Geraldo Alckmin met with Vice President Frans Timmermans of the EU Commission in Brasília. During his visit to Brazil, Timmermans said that President Lula's efforts to end destruction in the Amazon deserves support and cooperation from the European Union, adding that the EU could donate up to €750,000 to help the Yanomami people facing a humanitarian crisis. In March 2023, the EU's commissioner for competition Margrethe Vestager met with Vice President Alckmin and other Brazilian officials during a meeting in Brasília to unveil the EU-Brazil bilateral Investment Map. In June 2023, Lula met with EU president Ursula von der Leyen to discuss areas such as environment, science and technology and trade, namely the EU-Mercosur trade deal. Lula expressed concerns over a European Union's side letter proposal of sanctioning Mercosur goods in case they fail to meet environmental goals saying that "between partners there should be mutual confidence not mistrust and sanctions" and that the sanctions could hurt genuine Brazilian green efforts. During the meeting the European Union pledged to donate 20 million euros to the Amazon Fund. In July 2023, numerous Latin American, Caribbean and European leaders, including Lula, attended the III EU-CELAC summit in Brussels to discuss topics such as global hunger, inequalities, poverty and climate change. On the sidelines of the summit, Lula made the case for the EU-Mercosur trade deal and expressed concern for protectionist policies in the agreement.
A 4th period, also described as "The third style" receives strong influence from Chinese painting, a result of the artistic activity and expansion of the Tang dynasty. The civilization of Kucha, with the whole Tarim Basin from Turfan to Khotan, fell to the Chinese punitive invasion of 648 CE, putting an end to the Indo-Iranian styles of Kucha. Ashina She'er, the East Turkic general leading the Tang dynasty expeditionary corps, ordered the execution of eleven thousand Kuchean inhabitants by decapitation. It was recorded that "he destroyed five great towns and with them many myriads of men and women... the lands of the west were seized with terror." Two caves at Kizil have art of the Tang period: cave 43 and cave 229. In nearby Kumtura and in Turfan, Chinese styles now prevailed. In 670 CE, the Tibetan Empire conquered most of the Tarim Basin, including Khotan, Kucha, Karashahr and Kashgar, which they kept until the Chinese took back the control of the area in 692. In 753 CE, the northern part of the Tarim Basin was taken over by the Turks of the Uyghur Khaganate, based in Turfan. A new Tibetan conquest took place in 790 CE. By 900 CE, the area was under Muslim domination.
During the later stages of World War II, the entire Cold War, and to a lesser extent afterwards, uranium-235 has been used as the fissile explosive material to produce nuclear weapons. Initially, two major types of fission bombs were built: a relatively simple device that uses uranium-235 and a more complicated mechanism that uses plutonium-239 derived from uranium-238. Later, a much more complicated and far more powerful type of fission/fusion bomb (thermonuclear weapon) was built, that uses a plutonium-based device to cause a mixture of tritium and deuterium to undergo nuclear fusion. Such bombs are jacketed in a non-fissile (unenriched) uranium case, and they derive more than half their power from the fission of this material by fast neutrons from the nuclear fusion process.
Sources: en.wikipedia.org
== Bowfin body-shape evolution and development == The first fish lacked jaws and used negative pressure to suck their food in through their mouths. The jaw in the bowfin is a result of its evolutionary need to be able to catch and eat bigger and more nutritious prey. As a result of being able to gather more nutrients, the bowfin is able to live a more active lifestyle. The jaw of a bowfin has several adaptations. The maxilla and premaxilla are fused and the posterior chondrocranium articulates with the vertebra, which allows the jaw freedom to rotate. The suspensorium includes several bones and articulates with the snout, brain case, and mandible. When the jaw opens, epaxial muscles lift the chondrocranium, which is attached to the upper jaw, while adductor muscles act to close the lower jaw. This ability to open and close the jaw helps the bowfin to be an active predator that can catch bigger prey and digest them. The vertebral column in bowfin is ossified and in comparison to earlier fish, the centra are the major support for the body, whereas in earlier fish, the notochord was the main form of support. In the bowfin, neural spines and ribs also increase in prominence, an evolutionary aspect that helps provide additional support and stabilize unpaired fins. The evolution of the vertebral column allows the bowfin to withstand lateral bending that puts the column under compression without breaking. This, in turn, allows the bowfin to have more controlled and powerful movements, in comparison to fish that have only a notochord.
== History == Leveraging advanced computational bioinformatics, brilacidin and other defensin mimetics were first developed by University of Pennsylvania-based researchers. Their efforts were consolidated, and officially incorporated, in 2002, under the company name PolyMedix. PolyMedix conducted pre-clinical and clinical research with brilacidin through a completed Phase 2a human clinical trial with positive results. After discontinuing a clinical trial for an unrelated compound PolyMedix filed for Chapter 7 bankruptcy protection on 1 April 2013. Cellceutix acquired the PolyMedix assets and intellectual property, including the licenses and patents for brilacidin and the rest of the HDP-mimetic pipeline, from bankruptcy court which on 4 September 2013, approved Cellceutix's stalking horse bid. On 7 June 2017, Cellceutix Announced a Company Name Change to Innovation Pharmaceuticals Inc. On 9 June 2017, the stock ticker name was effectively changed to "IPIX".
Mahathir also strengthened political and economic cooperation with China, whilst maintaining diplomatic ambivalence on security issues to avoid escalating territorial disputes in the South China Sea. He openly criticised China's involvement in Malaysia's communist insurgency, but downplayed any military threat from China after the Cold War ended. In 1985, Mahathir visited China for the first time as prime minister, where he met Chinese leader Deng Xiaoping, establishing a new level of trust that laid the foundation for Malaysia-China relations and set the stage for decades of economic and diplomatic growth. Later, he visited China again in 1993, 1994, 1996, 1999, and twice in 2001. In the early 1990s, Mahathir played a key role in engaging China with ASEAN despite South China Sea disputes, particularly in the post-Tiananmen and post-Cold War contexts, paving the way for then Chinese Foreign Minister Qian Qichen to attend the ASEAN meeting's opening ceremony in July 1991 as a guest of the Malaysian government, and eventually leading to China's upgrade to ASEAN's dialogue partner in 1996. Amidst the Asian financial crisis, Mahathir also led several large delegations to China and Russia to seek regional economic cooperation. Besides that, Mahathir also had significant interactions with Taiwan, especially during the 1980s and 1990s, when economic ties between the two sides were at their strongest despite the lack of formal diplomatic relations.
Particle analysis by scanning electron microscope equipped with an energy-dispersive X-ray spectroscopy detector is the most powerful forensic tool that investigators can use to determine a subject's proximity to a discharging firearm or contact with a surface exposed to GSR (firearm, spent cartridge case, target hole). Test accuracy requires procedures that avoid secondary gunshot residue transfer from police officers onto subjects or items to be tested, and that avoid contamination in the laboratory. The two main groups of specialists currently active on gunshot residue analysis are the Scientific Working Group for Gunshot Residue (SWGGSR) based in USA and the ENFSI EWG Firearms/GSR Working Group based in Europe.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.